• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素受体抗体孵育时间及乳腺浸润性癌中免疫反应性程度:优化抗体亲和力的重要性

Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity.

作者信息

Goldstein Neal S, Hunter Susan, Forbes Suzy, Odish Eva, Tehrani Matab

机构信息

Department of Anatomic Pathology, William Beaumont Hospital, Royal Oak, MI 48073, USA.

出版信息

Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):203-7. doi: 10.1097/01.pai.0000209861.90086.58.

DOI:10.1097/01.pai.0000209861.90086.58
PMID:17525635
Abstract

We noticed that the percentage and intensity of estrogen receptor (ER) antibody (Ab) AB ER 1D5 immunohistochemical (IHC) staining was altered by Ab incubation time and the type of chromogen detection system in invasive breast carcinomas. We studied the impact of these 2 factors on Ab ER 1D5 immunoreactivity. Serial sections from 22 strongly ER-positive invasive breast carcinomas were immunohistochemically stained with Ab clone ER 1D5 using 3 IHC protocols. One IHC protocol used a 12-hour Ab incubation and a supersensitive, labeled streptavidin-biotin chromogen detection system (12 h-Standard), the second IHC protocol used a 2-hour Ab incubation and a supersensitive, labeled streptavidin-biotin chromogen detection system (2 h-SS), and the third protocol used a 2-hour Ab incubation and a polymer-based detection system (2 h-Env). Twenty identical fields on each slide stained with each IHC protocol were evaluated and staining was quantified using image analysis. The mean staining percentages using the 12 h-Standard, 2 h-SS, and 2 h-Env IHC staining protocols were 89%, 72%, and 47%, respectively (P<0.001). Three of the 22 cases (14%) were ER negative (<10% stained area) with the 2 h-Env IHC protocol. Stain intensity was significantly stronger with the 12 h-Standard Ab incubation IHC protocol than either 2-hour Ab incubation protocol (P<0.001). Twelve cases stained with 2-hour Ab incubation IHC protocols had weak visually seen staining: 7 were Allred total score 2 (ER negative) and 5 were Allred total score 3. Ab ER 1D5 avidity is directly related to factors that impact electrostatic forces, one of which is Ab incubation time. Standard automated stainer Ab incubation times of less than 1 hour may be of insufficient duration and result in artificially low levels of ER immunoreactivity. The chromogen detection system in association with the ER 1D5 Ab also alters levels of immunoreactivity. Optimization of IHC staining protocols should include evaluating the Ab incubation time and chromogen detection system. These factors can substantially alter the extent and intensity of ER IHC staining.

摘要

我们注意到,在浸润性乳腺癌中,雌激素受体(ER)抗体(Ab)AB ER 1D5免疫组化(IHC)染色的百分比和强度会因抗体孵育时间和显色剂检测系统的类型而改变。我们研究了这两个因素对Ab ER 1D5免疫反应性的影响。使用3种免疫组化方案,对22例ER强阳性浸润性乳腺癌的连续切片进行Ab克隆ER 1D5免疫组化染色。一种免疫组化方案采用12小时抗体孵育和超敏的标记链霉亲和素-生物素显色剂检测系统(12小时标准方案),第二种免疫组化方案采用2小时抗体孵育和超敏的标记链霉亲和素-生物素显色剂检测系统(2小时超敏方案),第三种方案采用2小时抗体孵育和基于聚合物的检测系统(2小时增强方案)。对每张玻片上用每种免疫组化方案染色的20个相同视野进行评估,并使用图像分析对染色进行定量。采用12小时标准方案、2小时超敏方案和2小时增强方案免疫组化染色的平均染色百分比分别为89%、72%和47%(P<0.001)。在2小时增强方案免疫组化染色中,22例病例中有3例(14%)ER阴性(染色面积<10%)。12小时标准抗体孵育免疫组化方案的染色强度明显强于两种2小时抗体孵育方案(P<0.001)。采用2小时抗体孵育免疫组化方案染色的12例病例肉眼可见染色较弱:7例为阿尔雷德总分2分(ER阴性),5例为阿尔雷德总分3分。Ab ER 1D5的亲和力与影响静电力的因素直接相关,其中之一是抗体孵育时间。标准自动染色仪的抗体孵育时间少于1小时可能持续时间不足,并导致ER免疫反应性人为降低。与ER 1D5抗体相关的显色剂检测系统也会改变免疫反应性水平。免疫组化染色方案的优化应包括评估抗体孵育时间和显色剂检测系统。这些因素可显著改变ER免疫组化染色的程度和强度。

相似文献

1
Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity.雌激素受体抗体孵育时间及乳腺浸润性癌中免疫反应性程度:优化抗体亲和力的重要性
Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):203-7. doi: 10.1097/01.pai.0000209861.90086.58.
2
Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays.韩国女性浸润性乳腺癌中激素受体的表达及 3 种抗雌激素受体抗体的比较:使用组织微阵列的多机构回顾性研究。
Am J Surg Pathol. 2012 Dec;36(12):1817-25. doi: 10.1097/PAS.0b013e318267b012.
3
A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results.雌激素受体SP1和1D5单克隆抗体在常规临床应用中的比较显示出相似的染色结果。
Am J Clin Pathol. 2009 Sep;132(3):396-401. doi: 10.1309/AJCPSKFWOLPPMEU9.
4
Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.采用抗原修复技术,对甲醇-氯仿固定的石蜡包埋乳腺癌组织进行雌激素和孕激素受体的免疫组织化学检测。
J Surg Res. 1996 Jan;60(1):69-73. doi: 10.1006/jsre.1996.0012.
5
Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.转移性乳腺癌细胞学标本中的叶酸受体α免疫组织化学
Acta Cytol. 2015;59(4):298-304. doi: 10.1159/000440796. Epub 2015 Sep 29.
6
Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers.用于雌激素受体(ER)报告的艾尔雷德评分及其在清晰区分ER阴性和ER阳性乳腺癌方面的影响。
J Pak Med Assoc. 2010 May;60(5):350-3.
7
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.使用新型兔单克隆抗体SP1对乳腺癌雌激素受体进行免疫组织化学检测,在预测生存率方面优于小鼠单克隆抗体1D5。
J Clin Oncol. 2006 Dec 20;24(36):5637-44. doi: 10.1200/JCO.2005.05.4155. Epub 2006 Nov 20.
8
Immunocytochemical evaluation of estrogen receptor on archival Papanicolaou-stained fine-needle aspirate smears.对存档的巴氏染色细针穿刺涂片上雌激素受体进行免疫细胞化学评估。
Diagn Cytopathol. 2003 Dec;29(6):309-14. doi: 10.1002/dc.10348.
9
Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy.开发用于选择抗激素治疗患者的标准雌激素和孕激素受体免疫组织化学检测方法。
Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):325-31. doi: 10.1097/01.pai.0000213135.16783.bc.
10
Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer.原发性乳腺癌雌激素受体和HER2的免疫组织化学双重染色
Int J Mol Med. 2003 Dec;12(6):855-9.

引用本文的文献

1
Biomarker development for axial spondyloarthritis.轴向型脊柱关节炎的生物标志物研发。
Nat Rev Rheumatol. 2020 Aug;16(8):448-463. doi: 10.1038/s41584-020-0450-0. Epub 2020 Jun 30.
2
Use of archived specimens in evaluation of prognostic and predictive biomarkers.存档标本在评估预后和预测生物标志物中的应用。
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.